VJHemOnc is committed to improving our service to you

ASH 2019 | Uproleselan update: moving forward for R/R AML

VJHemOnc is committed to improving our service to you

Daniel DeAngelo

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the latest data on uproleselan (GMI-1271), a novel E-selectin antagonist, in acute myeloid leukemia (AML). This includes the upcoming phase 3 registration trial in the relapsed/refractory setting (NCT03616470) and work showing that uproleselan can overcome the chemotherapy resistance that high E-selectin ligand expression contributes to. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter